Development of vaccines for Marburg hemorrhagic fever

被引:13
作者
Bousch, Daniel G.
Geisbert, Thomas W.
机构
[1] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA 70112 USA
[2] USA, Med Res Inst Infect Dis, Dept Viral Pathol & Ultrastruct, Div Virol, Ft Detrick, MD 21702 USA
[3] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
关键词
Filoviridae; filovirus; Marburg hemorrhagic fever; Marburg virus; pathogenesis; vaccines;
D O I
10.1586/14760584.6.1.57
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Marburg (MARV) and Ebola viruses (EBOV) emerged from the rainforests; of Central Africa more than 30 years ago causing outbreaks of severe and, usually, fatal hemorrhagic fever. EBOV has garnered the lion's share of the attention, fueled by the higher frequency of EBOV outbreaks, high mortality rates and importation into the USA, documented in such popular works as the best-selling novel 'The Hot Zone'. However, recent large outbreaks of hundreds of cases of MARV infection in the Democratic Republic of the Congo and Angola with case fatalities approaching 90% dramatically highlight its lethal potential. Although no vaccines or antiviral drugs for MARV are currently available, remarkable progress has been made over the last few years in developing potential countermeasures against MARV in nonhuman primate models. In particular, a vaccine based on attenuated recombinant vesicular stomatitis virus was recently shown to have both preventive and postexposure efficacy.
引用
收藏
页码:57 / 74
页数:18
相关论文
共 158 条
[1]  
AGAFONOV AP, 1992, VOP VIRUSOL+, V37, P58
[2]  
Agafonova OA, 1997, VOP VIRUSOL+, V42, P109
[3]  
ALIBEK K, 1999, WORLD
[4]  
ALMEIDA J D, 1971, P84
[5]  
Amorosa VK, 2003, CLIN INFECT DIS, V37, P426, DOI 10.1086/375823
[6]   VP24 of Marburg virus influences formation of infectious particles [J].
Bamberg, S ;
Kolesnikova, L ;
Möller, P ;
Klenk, HD ;
Becker, S .
JOURNAL OF VIROLOGY, 2005, 79 (21) :13421-13433
[7]   Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].
Barouch, DH ;
Pau, MG ;
Custers, JHHV ;
Koudstaal, W ;
Kostense, S ;
Havenga, MJE ;
Truitt, DM ;
Sumida, SM ;
Kishko, MG ;
Arthur, JC ;
Korioth-Schmitz, B ;
Newberg, MH ;
Gorgone, DA ;
Lifton, MA ;
Panicali, DL ;
Nabel, GJ ;
Letvin, NL ;
Goudsmit, J .
JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297
[8]   The Ebola virus VP35 protein functions as a type IIFN antagonist [J].
Basler, CF ;
Wang, XY ;
Mühlberger, E ;
Volchkov, V ;
Paragas, J ;
Klenk, HD ;
Garcia-Sastre, A ;
Palese, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12289-12294
[9]   Marburg hemorrhagic fever associated with multiple genetic lineages of virus [J].
Bausch, Daniel G. ;
Nichol, Stuart T. ;
Muyembe-Tamfum, Jean Jacques ;
Borchert, Matthias ;
Rollin, Pierre E. ;
Sleurs, Hilde ;
Campbell, Patricia ;
Tshioko, Florimund K. ;
Roth, Catherine ;
Colebunders, Robert ;
Pirard, Patricia ;
Mardel, Simon ;
Olinda, Loku A. ;
Zeller, Herve ;
Tshomba, Antoine ;
Kulidri, Amayo ;
Libande, Modeste L. ;
Mulangu, Sabue ;
Formenty, Pierre ;
Grein, Thomas ;
Leirs, Herwig ;
Braack, Leo ;
Ksiazek, Tom ;
Zaki, Sherif ;
Bowen, Michael D. ;
Smit, Sheilagh B. ;
Leman, Patricia A. ;
Burt, Felicity J. ;
Kemp, Alan ;
Swanepoel, Robert .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) :909-919
[10]   Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo [J].
Bausch, DG ;
Borchert, M ;
Grein, T ;
Roth, C ;
Swanepoel, R ;
Libande, ML ;
Talarmin, A ;
Bertherat, E ;
Muyembe-Tamfum, JJ ;
Tugume, B ;
Colebunders, R ;
Kondé, KM ;
Pirard, P ;
Olinda, LL ;
Rodier, GR ;
Campbell, P ;
Tomori, O ;
Ksiazek, TG ;
Rollin, PE .
EMERGING INFECTIOUS DISEASES, 2003, 9 (12) :1531-1537